184 related articles for article (PubMed ID: 18574983)
1. [2008 National Cardiology Guidelines: Prioritization requires consideration to other factors than scientific studies alone].
Eklund K; Grip L; Israelsson B; Levin LA; Lindahl B; Wallentin L
Lakartidningen; 2008 May 7-13; 105(19):1408-9; discussion 1409. PubMed ID: 18574983
[No Abstract] [Full Text] [Related]
2. [Lean years for patients].
Klose G; Anlauf M
MMW Fortschr Med; 2004 Dec; 146(51-52):16. PubMed ID: 15675237
[No Abstract] [Full Text] [Related]
3. [Pfizer: TLV decision about antilipemic agents is founded on wrong basis].
Brun J; Ohlsson-Onerud A; Sörensen N
Lakartidningen; 2009 Apr 22-28; 106(17):1193-4; discussion 1194. PubMed ID: 19530431
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
[TBL] [Abstract][Full Text] [Related]
5. [Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
Weizel A; Sawicki PT
MMW Fortschr Med; 2004 Dec; 146(51-52):14, 16. PubMed ID: 15675236
[No Abstract] [Full Text] [Related]
6. [SBU should investigate what is an evidence-based and cost-effective use of statins].
Hjemdahl P; Allhammar A; Heaton C; Hulting J; Kahan T; Malmström R; Martinsson A; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B
Lakartidningen; 2009 Aug 5-18; 106(32-33):1992-4. PubMed ID: 19764381
[No Abstract] [Full Text] [Related]
7. What price atorvastatin?
Drug Ther Bull; 2012 Jul; 50(7):73. PubMed ID: 22764068
[No Abstract] [Full Text] [Related]
8. Integrating economic analysis into clinical trials.
Imai K; Zhang P
Lancet; 2005 May 21-27; 365(9473):1749-50. PubMed ID: 15910936
[No Abstract] [Full Text] [Related]
9. Potential neurological value of statins increases.
Bonetta L
Nat Med; 2002 Jun; 8(6):541. PubMed ID: 12042786
[No Abstract] [Full Text] [Related]
10. Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.
Simpson RJ; Signorovitch J; Ramakrishnan K; Ivanova J; Birnbaum H; Kuznik A
Am J Ther; 2011 Nov; 18(6):436-48. PubMed ID: 20802306
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS.
Lafuma A; Colin X; Solesse A
Arch Cardiovasc Dis; 2008 May; 101(5):327-32. PubMed ID: 18656091
[TBL] [Abstract][Full Text] [Related]
12. [How far the rates of cholesterol have to be lowered in primary prevention?].
Rodondi N
Rev Med Suisse; 2010 Mar; 6(239):483-4. PubMed ID: 20373693
[No Abstract] [Full Text] [Related]
13. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
15. Statins: not just for the young or the faint of heart.
Coull BM; Johnston SC
Neurology; 2009 Feb; 72(8):684-5. PubMed ID: 19237695
[No Abstract] [Full Text] [Related]
16. The pharmaco-economics of peri-operative statin therapy.
Biccard BM; Sear JW; Foëx P
Anaesthesia; 2005 Nov; 60(11):1059-63. PubMed ID: 16229688
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of high-dose atorvastatin compared with usual-dose simvastatin: less than IDEAL?
Kaul P
Eur Heart J; 2007 Jun; 28(12):1405-6. PubMed ID: 17553925
[No Abstract] [Full Text] [Related]
18. Cardiovascular primary prevention: how high should we set the bar?
Prasad V; Vandross A
Arch Intern Med; 2012 Apr; 172(8):656-9; discussion 659. PubMed ID: 22529231
[TBL] [Abstract][Full Text] [Related]
19. Statins for millions more?
Lancet; 2014 Feb; 383(9918):669. PubMed ID: 24560042
[No Abstract] [Full Text] [Related]
20. A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study.
Arikian S
Clin Ther; 2000 Apr; 22(4):494-6. PubMed ID: 10823368
[No Abstract] [Full Text] [Related]
[Next] [New Search]
